WALTHAM, Mass., March  17, 2026  (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with

Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting

Xilio Therapeutics to Present Key Research at AACR Annual Meeting

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>WALTHAM, Mass., March  17, 2026  (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Xilio Therapeutics will showcase its masked T cell engager XTX601 at the AACR Annual Meeting in April. This presentation could highlight promising advancements in their immuno-oncology therapies, potentially affecting investor sentiment and future stock performance.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Xilio to present at AACR Annual Meeting in April 2026.</li><li>The poster focuses on XTX601, targeting Claudin 18.2.</li><li>Presentation scheduled for April 20, 2026, in San Diego.</li><li>Xilio develops masked immuno-oncology therapies improving patient outcomes.</li><li>Current R&amp;D progress is crucial for future product pipeline.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>AbbVie (ABBV)</strong>: Xilio&#039;s collaboration may enhance its clinical capabilities.</li><li><strong>Gilead (GILD)</strong>: Potential partnerships could improve pipeline transparency and financial stability.</li><li><strong>Roche (RHHBY)</strong>: Support from Roche may facilitate faster clinical advancements for Xilio.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This announcement falls under &#039;Corporate Developments&#039; as it showcases Xilio&#039;s efforts in advancing its pipeline and participation in a major conference. Such developments are pivotal for clinical-stage biotechnology firms seeking investment and visibility.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>XTX601&#039;s efficacy could drive future collaborations and funding.</li><li>Positive reception at AACR may enhance stock liquidity and price stability.</li><li>Upcoming clinical trial results can further validate Xilio&#039;s pipeline.</li><li>Partnerships with AbbVie and Gilead could accelerate product development.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Xilio&#039;s presentation is on April 20, 2026.</li><li>Session focused on T cell engagers within immunology.</li><li>Presentation location is Poster Section 10, Board 11.</li><li>Xilio develops therapies to reduce systemic side effects for cancer patients.</li><li>Claudin 18.2 targeting technology is a key component of Xilio&#039;s research.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should consider a bullish stance on XLO leading up to AACR.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">WALTHAM, Mass., March  17, 2026  (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/XLO">XLO</a>), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 17-22, 2026 at the San Diego Convention Center in San Diego, California.</p>  <p>Poster presentation details, as follows:</p>  <p><strong>Title: </strong>Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager<br></br><strong>Session Category:</strong> Immunology<br></br><strong>Session Title:</strong> T Cell Engagers 1<br></br><strong>Session Date and Time:</strong> Monday, Apr. 20, 2026, from 9:00 a.m. to 12:00 p.m. PST<br></br><strong>Location:</strong> Poster Section 10<br></br><strong>Poster Board:</strong> 11<br></br><strong>Abstract Number:</strong> 1619</p>  <p><strong>About Xilio Therapeutics</strong></p>  <p align="justify">Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Leveraging our clinically-validated masking technology and capabilities, Xilio is developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Learn more by visiting <a href="https://www.globenewswire.com/Tracker?data=FgtnVkaBKCTuXrwi_9xnKvqlFx9pDw5iUyL8lEGqD7ld0EzBjBMuGAJbhM79z3qb_bBoI9GFcsuE9TJIxDNVVQ==" rel="nofollow" target="_blank">www.xiliotx.com</a> and follow us on <a href="https://www.globenewswire.com/Tracker?data=Ho0QPO5yc7EgGKvRWTO01v0vA2R8cpcL6DCZwmvK_Oh7ixDTqe6GGrgvFNUZ83TWiKwbKunMXwvoKo5RMz42XWKMwXK_q5-Sj3bT3I2I5rs=" rel="nofollow" target="_blank">LinkedIn</a>.</p>  <p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>  <p align="justify">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans to present data related to Xilio's masked T cell engager program targeting CLDN18.2. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "seek," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks related to general market conditions and geopolitical uncertainties; risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials; the delay of any current or planned preclinical studies or clinical trials or the development of Xilio's current or future product candidates; Xilio's need to obtain additional cash resources to advance its pipeline of tumor-activated I-O molecules; the impact of international trade policies on Xilio's business, including U.S. and China trade policies; and Xilio's ability to maintain its collaboration or partnership agreements with AbbVie, Gilead and Roche. These and other risks and uncertainties are described in greater detail in the sections entitled "Risk Factor Summary" and "Risk Factors" in Xilio's filings with the SEC, including Xilio's most recent Quarterly Report on Form 10-Q and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements.</p>  <p align="justify">This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.</p>  <p><strong>Investor Contact</strong><br></br>Alex Lobo, Precision AQ<br></br><a href="https://www.globenewswire.com/Tracker?data=iO_l8VYDfP2m58kceRL6XhO_1uB3f2CXtsLlj3tW2sF-GY4UhMI7N0yQNqR9pl9kGXhCQPfqnLqNwvWB7SXAxXGQeHjVMySL5F8S8kjUH2dDZ0LGuUFJy7q4QfB24Ka5" rel="nofollow" target="_blank">alex.lobo@precisionaq.com</a></p>  <p><strong>Media Contact</strong><br></br>Josie Butler, 1AB<br></br><a href="https://www.globenewswire.com/Tracker?data=00GsyLPSwKgiAOv6qSQ6MlUaFWuEJFUA9Qyvfz2YNl1R2cdkdKLAnqfDnSgi-UmRDSHMHKZXgYIJ4tArkt7JVKHUlZhyUdce5p7bX1NfwDc=" rel="nofollow" target="_blank">josie@1abmedia.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3MzY1OCM3NDkwMTM0IzIyMDk4MDQ="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NWIyZDJiZDktMzFiNy00NmZjLTlkMTItNTQwYmIxYTRiNjEwLTEyMjEzNTctMjAyNi0wMy0xNy1lbg==/tiny/Xilio-Therapeutics-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/7e55cc25-f46f-423c-bf2a-e77ebaf69665"><img src="https://ml.globenewswire.com/media/7e55cc25-f46f-423c-bf2a-e77ebaf69665/small/xilio-full-clr-logo-cmyk-png.png" border="0" width="150" height="94" alt="Primary Logo"></img></a></p>

Xilio Therapeutics will showcase its masked T cell engager XTX601 at the AACR Annual Meeting in April. This presentation could highlight promising advancements in their immuno-oncology therapies, potentially affecting investor sentiment and future stock performance.

xilio-therapeutics-to-present-new-preclinical-data-for-its-masked-t-cell-engager-program-targeting-cldn18-2-at-the-american-association-for-cancer-research-aacr-annual-meeting

Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News